107 related articles for article (PubMed ID: 27918349)
1. Soft Palate Ulcer: An Unusual Presentation of a Posttransplant Lymphoproliferative Disorder.
Bahmanyar M; Shakibazad N; Imanieh MH; Dehghani SM
J Pediatr Hematol Oncol; 2017 Mar; 39(2):e97-e99. PubMed ID: 27918349
[TBL] [Abstract][Full Text] [Related]
2. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Trappe RU; Dierickx D; Zimmermann H; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Salles G; Kliem V; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S
J Clin Oncol; 2017 Feb; 35(5):536-543. PubMed ID: 27992268
[TBL] [Abstract][Full Text] [Related]
3. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
4. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
5. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center.
Mamzer-Bruneel MF; Lomé C; Morelon E; Levy V; Bourquelot P; Jacobs F; Gessain A; Mac Intyre E; Brousse N; Kreis H; Hermine O
J Clin Oncol; 2000 Nov; 18(21):3622-32. PubMed ID: 11054435
[TBL] [Abstract][Full Text] [Related]
6. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
7. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation.
Choquet S; Trappe R; Leblond V; Jäger U; Davi F; Oertel S
Haematologica; 2007 Feb; 92(2):273-4. PubMed ID: 17296588
[TBL] [Abstract][Full Text] [Related]
8. Angioimmunoblastic T cell lymphoma: an unusual presentation of posttransplant lymphoproliferative disorder in a pediatric patient.
Kraus TS; Twist CJ; Tan BT
Acta Haematol; 2014; 131(2):95-101. PubMed ID: 24157860
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
Zimmermann H; Babel N; Dierickx D; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Bachy E; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S; Trappe RU
Transplantation; 2018 Nov; 102(11):1914-1923. PubMed ID: 29757894
[TBL] [Abstract][Full Text] [Related]
10. Variant of classical high grade PTLD: post-transplant EBV-negative T cell lymphoblastic leukaemia after solid organ transplantation.
Teiken K; Kreipe H; Maecker-Kolhoff B; Hussein K
Ann Hematol; 2017 Aug; 96(8):1403-1405. PubMed ID: 28616657
[No Abstract] [Full Text] [Related]
11. Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Williams KM; Higman MA; Chen AR; Schwartz CL; Wharam M; Colombani P; Arceci RJ
Pediatr Blood Cancer; 2008 Mar; 50(3):667-70. PubMed ID: 17318876
[TBL] [Abstract][Full Text] [Related]
12. Post-Transplant Lymphoproliferative Disorder (PTLD) Manifesting in the Oral Cavity of a 13-Year-Old Liver Transplant Recipient (LTx).
Krasuska-Sławińska E; Minko-Chojnowska I; Pawłowska J; Dembowska-Bagińska B; Pronicki M; Olczak-Kowalczyk D
Ann Transplant; 2015 Aug; 20():478-82. PubMed ID: 26285106
[TBL] [Abstract][Full Text] [Related]
13. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
[TBL] [Abstract][Full Text] [Related]
14. Remission of Late-Onset Post-Liver Transplantation Non-Hodgkin Lymphoma.
Stardelova KG; Stojanovik A; Jovanovska RP; Stavrik S; Dimitrova M; Kostova NM; Serafimoski V
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2019 May; 40(1):67-71. PubMed ID: 31152642
[TBL] [Abstract][Full Text] [Related]
15. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab.
Trappe RU; Choquet S; Reinke P; Dreyling M; Mergenthaler HG; Jäger U; Kebelmann-Betzing C; Jonas S; Lehmkuhl H; Anagnostopoulos I; Leblond V; Hetzer R; Dörken B; Riess H; Oertel S
Transplantation; 2007 Dec; 84(12):1708-12. PubMed ID: 18165786
[TBL] [Abstract][Full Text] [Related]
16. Recurrent posttransplant lymphoproliferative disorder involving the larynx and trachea: case report and review of the literature.
Banks CA; Meier JD; Stallworth CR; White DR
Ann Otol Rhinol Laryngol; 2012 May; 121(5):291-5. PubMed ID: 22724273
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen.
Fohrer C; Caillard S; Koumarianou A; Ellero B; Woehl-Jaeglé ML; Meyer C; Epailly E; Chenard MP; Lioure B; Natarajan-Ame S; Maloisel F; Lutun P; Kessler R; Moulin B; Bergerat JP; Wolf P; Herbrecht R
Br J Haematol; 2006 Sep; 134(6):602-12. PubMed ID: 16889621
[TBL] [Abstract][Full Text] [Related]
18. Posttransplant monomorphic Burkitt's lymphoma: clinical characteristics and outcome of a multicenter series.
Bobillo S; Abrisqueta P; Sánchez-González B; Giné E; Romero S; Alcoceba M; González-Barca E; González de Villambrosía S; Sancho JM; Gómez P; Bento L; Montoro J; Montes S; López A; Bosch F;
Ann Hematol; 2018 Dec; 97(12):2417-2424. PubMed ID: 30116871
[TBL] [Abstract][Full Text] [Related]
19. Burkitt-like post-transplant lymphoproliferative disorder (PTLD) presenting with breast mass in a renal transplant recipient: a report of a rare case.
Law MF; Chan HN; Leung C; Lai HK; Ha CY; Ng C; Yeung YM; Yip SF
Ann Hematol; 2014 Dec; 93(12):2083-5. PubMed ID: 24782123
[No Abstract] [Full Text] [Related]
20. Gastric Mucosa-associated Lymphoid Tissue Lymphoma: Posttransplant Lymphopoliferative Disorder.
Tu S; Zhong D; Wu X; Li Y; Song C
Am J Med Sci; 2016 Oct; 352(4):439-441. PubMed ID: 27776731
[No Abstract] [Full Text] [Related]
[Next] [New Search]
